Clinical Trial

Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicentre, Open-label, Randomised, Phase 3 Trial

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 7, 2022 (before its estimated May 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aims to carry out a multi-center, randomized controlled study on patients with recurrent ovarian cancer after PARPi maintenance, to explore the clinicopathological and molecular characteristics of patients with recurrent ovarian cancer after PARPi maintenance, and to clarify whether patients with recurrent ovarian cancer after PARPi maintenance for more than 6 months are sensitive to platinum drugs, and the value of secondary tumor cell reduction in such treatment, In order to provide evidence-based medicine basis for the standardized treatment mode of recurrent ovarian cancer after PARPi maintenance treatment.
Trial Details
NCT Number NCT05607329
Lead Sponsor Women's Hospital School Of Medicine Zhejiang University
Conditions Relapsed Ovarian Cancer
Enrollment 400 participants
Start Date 2021-05-01
Primary Completion 2026-05-01 (estimated)
Study Completion 2028-05-01 (estimated)
Updated on ClinicalTrials.gov 2022-11-07